2021
Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function
Ramachandran R, Prabakaran R, Priya G, Nayak S, Kumar P, Kumar A, Kumar V, Agrawal N, Rathi M, Kohli H, Nada R. Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function. Nephron 2021, 146: 138-145. PMID: 34818240, DOI: 10.1159/000518609.Peer-Reviewed Original ResearchConceptsPMN patientsRenal dysfunctionAnti-PLA2RClinical remissionInduce remissionMembranous nephropathyFollow-upPrimary membranous nephropathyCompromised renal functionEnd-stage renal diseaseAdverse event profileProspective longitudinal observational studyPercentage of patientsCKD stage 3Immunosuppressive therapyImmunosuppressive treatmentLongitudinal observational studyRenal functionEvent profileCKD stageClinical outcomesUnit protocolRemissionNephrotic stateRenal disease
2015
PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians
Ramachandran R, Kumar V, Kumar A, Yadav A, Nada R, Kumar H, Kumar V, Rathi M, Kohli H, Gupta K, Sakhuja V, Jha V. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians. Nephrology Dialysis Transplantation 2015, 31: 1486-1493. PMID: 26673907, DOI: 10.1093/ndt/gfv399.Peer-Reviewed Original ResearchConceptsAnti-PLA2R titerHLA-DQA1 geneAnti-PLA2RHLA-DQA1Glomerular stainingAssociated with PMNAntibodies to m-type phospholipase A2 receptorNephrotic stateM-type phospholipase A2 receptorRemission of nephrotic syndromeAnti-PLA2R levelsAnti-PLA2R positivityGlomerular PLA2R depositionGlomerular PLA2R stainingSerum anti-PLA2RMonths of therapyPhospholipase A2 receptorResponse to therapyHigh-risk genotypesResponse to treatmentFresh frozen tissuePLA2R stainingPMN patientsPLA2R antibodyA2 receptors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply